Curevac advances seasonal flu study to phase 2 in collaboration with gsk following selection of promising mrna vaccine candidate with broad coverage

Phase 1 part of combined phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mrna constructs per candidate best-performing candidate providing broad antigen coverage against who-recommended flu strains selected for phase 2, following positive data from phase 1 interim analysis dosing of first phase 2 participant anticipated in q4 2023; phase 2 to include older adults and standard-of-care comparison tÜbingen, germany and boston, ma / accesswire / september 12, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced selection of a promising vaccine candidate for continued clinical development based on positive data from an interim analysis of the ongoing phase 1 part of a combined phase 1/2 study, conducted in collaboration with gsk.
CVAC Ratings Summary
CVAC Quant Ranking